Table 2. In Vitro Cytotoxic Potency of the Newly Synthesized Compounds 2–8 against Various Human Cancer Cell Lines and Normal Cells Representing SI of the Most Active Derivativesa.
IC50 (mean ± SEM) (μM) |
|||||
---|---|---|---|---|---|
compd. no. | HepG-2 | PC-3 | MCF-7 | A-549 | PBMC |
2a | 57.85 ± 0.07 | 26.82 ± 2.21 | 37.73 ± 0.08 | 34.57 ± 0.06 | 121.34 ± 11.35 |
2b | 60.85 ± 0.06 | 44.50 ± 3.51 | 55.44 ± 0.04 | 57.48 ± 0.05 | 133.30 ± 13.67 |
2c | 47.66 ± 0.04 | 25.44 ± 0.04 | 21.76 ± 0.08 | 27.81 ± 0.04 | 144.56 ± 14.89 |
2d | 34.77 ± 0.03 | 39.32 ± 0.0 | 24.74 ± 0.08 | 20.84 ± 0.04 | 157.78 ± 16.35 |
2e | 37.76 ± 0.05 | 40.56 ± 0.05 | 25.64 ± 0.08 | 25.96 ± 0.05 | 168.54 ± 17.36 |
3 | 37.73 ± 0.02 | 17.29 ± 0.03 | 6.59 ± 0.07 | 10.42 ± 0.05 | 179.25 ± 18.75 |
4 | 56.65 ± 0.04 | 25.41 ± 0.05 | 8.32 ± 0.04 | 15.61 ± 0.06 | 186.68 ± 19.36 |
5a | 35.66 ± 0.04 | 16.49 ± 0.05 | 5.42 ± 0.05 | 10.37 ± 0.04 | 174.90 ± 18.24 |
SI = 4.90 | SI = 10.60 | SI = 32.26 | SI = 16.86 | ||
5b | 38.49 ± 0.02 | 18.22 ± 0.03 | 4.18 ± 0.03 | 8.27 ± 0.03 | 165.76 ± 17.36 |
SI = 4.30 | SI = 9.09 | SI = 39.65 | SI = 20.04 | ||
5c | 27.59 ± 0.04 | 18.44 ± 0.04 | 4.33 ± 0.04 | 12.30 ± 0.04 | 146.32 ± 16.15 |
SI = 5.23 | SI = 7.93 | SI = 33.79 | SI = 11.89 | ||
6a | 10.48 ± 0.03 | 16.30 ± 0.09 | 4.30 ± 0.04 | 5.20 ± 0.03 | 157.45 ± 16.89 |
SI = 15.02 | SI = 9.65 | SI = 36.61 | SI = 30.27 | ||
6b | 5.47 ± 0.02 | 13.21 ± 0.06 | 1.29 ± 0.03 | 3.18 ± 0.03 | 178.23 ± 17.69 |
SI = 32.58 | SI = 13.49 | SI = 138.16 | SI = 56.04 | ||
6c | 7.73 ± 0.04 | 26.41 ± 0.05 | 2.51 ± 0.06 | 5.80 ± 0.05 | 187.67 ± 19.76 |
SI = 24.27 | SI = 7.10 | SI = 74.76 | SI = 32.35 | ||
7 | 29.75 ± 0.03 | 17.90 ± 0.03 | 4.65 ± 0.07 | 7.43 ± 0.04 | 165.23 ± 18.05 |
8a | 59.84 ± 0.05 | 36.55 ± 0.03 | 13.75 ± 0.08 | 25.46 ± 0.05 | 173.45 ± 18.95 |
SI = 2.91 | SI = 4.74 | SI = 12.61 | SI = 6.81 | ||
8b | 60.48 ± 0.05 | 42.56 ± 0.06 | 17.95 ± 0.04 | 37.21 ± 0.03 | 196.67 ± 20.67 |
SI = 3.25 | SI = 4.62 | SI = 10.95 | SI = 5.28 | ||
8c | 45.49 ± 0.04 | 32.48 ± 0.04 | 10.31 ± 0.04 | 8.29 ± 0.03 | 188.89 ± 19.86 |
SI = 4.15 | SI = 5.81 | SI = 18.32 | SI = 22.78 | ||
8d | 47.86 ± 0.05 | 39.55 ± 0.08 | 14.77 ± 0.05 | 9.50 ± 0.06 | 179.09 ± 18.96 |
SI = 3.74 | SI = 4.52 | SI = 12.12 | SI = 18.85 | ||
DOX | 4.51 ± 0.26 | 8.11 ± 0.05 | 4.17 ± 0.2 | 8.20 ± 0.08 | 250.00 ± 26.56 |
SI = 55.43 | SI = 30.82 | SI = 59.95 | SI = 30.48 | ||
erlotinib | 8.19 ± 0.4 | 8.89 ± 0.6 | 4.16 ± 0.2 | 3.76 ± 0.2 | 45.75 ± 26.56 |
SI = 5.58 | SI = 5.14 | SI = 10.99 | SI = 12.16 |
DOX: doxorubicin; IC50: compound concentration required to inhibit the cell viability by 50%; SEM: standard error mean; each value is the mean of three independent determinations; SI: selectivity index.